Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Emory University
Milton S. Hershey Medical Center
Milton S. Hershey Medical Center
Memorial Sloan Kettering Cancer Center
Milton S. Hershey Medical Center
Milton S. Hershey Medical Center
Milton S. Hershey Medical Center
St. Jude Children's Research Hospital
New Approaches to Neuroblastoma Therapy Consortium
New Approaches to Neuroblastoma Therapy Consortium
Masonic Cancer Center, University of Minnesota
Memorial Sloan Kettering Cancer Center
Institut Curie
Nationwide Children's Hospital
M.D. Anderson Cancer Center
Sun Yat-sen University
Instituto do Cancer do Estado de São Paulo
Nationwide Children's Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Medical College of Wisconsin
Karolinska University Hospital
Children's National Research Institute
Fundació Sant Joan de Déu
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
University of California, San Francisco
Milton S. Hershey Medical Center
University of Birmingham
University of Cologne
University of Virginia
Fundació Sant Joan de Déu
Memorial Sloan Kettering Cancer Center
Children's Hospital Los Angeles
University of Iowa
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
New Approaches to Neuroblastoma Therapy Consortium
University Medicine Greifswald
University of Iowa
University of Iowa
University of Regensburg
M.D. Anderson Cancer Center
Baylor College of Medicine
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center